RU2007108861A - Трифтометилзамещенные бензамиды в качестве ингибиторов киназ - Google Patents
Трифтометилзамещенные бензамиды в качестве ингибиторов киназ Download PDFInfo
- Publication number
- RU2007108861A RU2007108861A RU2007108861/04A RU2007108861A RU2007108861A RU 2007108861 A RU2007108861 A RU 2007108861A RU 2007108861/04 A RU2007108861/04 A RU 2007108861/04A RU 2007108861 A RU2007108861 A RU 2007108861A RU 2007108861 A RU2007108861 A RU 2007108861A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- compound
- methyl
- ylmethyl
- group
- Prior art date
Links
- 229940054066 benzamide antipsychotics Drugs 0.000 title 1
- 150000003936 benzamides Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- XHEISHRKUMLZES-UHFFFAOYSA-N 3-isoquinolin-7-yl-4-methyl-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(C=2C=C3C=NC=CC3=CC=2)C(C)=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 XHEISHRKUMLZES-UHFFFAOYSA-N 0.000 claims 1
- SQNGPSFWLCMUMK-UHFFFAOYSA-N 4-[(4-methylpiperazin-1-yl)methyl]-n-(4-methyl-3-quinazolin-6-ylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(C(C)=CC=2)C=2C=C3C=NC=NC3=CC=2)C=C1C(F)(F)F SQNGPSFWLCMUMK-UHFFFAOYSA-N 0.000 claims 1
- OWMQRYCHOXSPEK-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-n-(3-isoquinolin-7-yl-4-methylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(CN(C)C)=CC=C1C(=O)NC1=CC=C(C)C(C=2C=C3C=NC=CC3=CC=2)=C1 OWMQRYCHOXSPEK-UHFFFAOYSA-N 0.000 claims 1
- VLTMZUJBRIXLPY-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-n-(4-methyl-3-phthalazin-6-ylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(CN(C)C)=CC=C1C(=O)NC1=CC=C(C)C(C=2C=C3C=NN=CC3=CC=2)=C1 VLTMZUJBRIXLPY-UHFFFAOYSA-N 0.000 claims 1
- KEJIZGVSPJNUSG-UHFFFAOYSA-N 4-methyl-3-phthalazin-6-yl-n-[4-(piperidin-1-ylmethyl)-3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1C(=O)NC(C=C1C(F)(F)F)=CC=C1CN1CCCCC1 KEJIZGVSPJNUSG-UHFFFAOYSA-N 0.000 claims 1
- KKVXPGXEJSXINH-UHFFFAOYSA-N 4-methyl-3-phthalazin-6-yl-n-[4-(pyrrolidin-1-ylmethyl)-3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1C(=O)NC(C=C1C(F)(F)F)=CC=C1CN1CCCC1 KKVXPGXEJSXINH-UHFFFAOYSA-N 0.000 claims 1
- DOOUPYSMBGVLED-UHFFFAOYSA-N 4-methyl-n-[4-(morpholin-4-ylmethyl)-3-(trifluoromethyl)phenyl]-3-phthalazin-6-ylbenzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1C(=O)NC(C=C1C(F)(F)F)=CC=C1CN1CCOCC1 DOOUPYSMBGVLED-UHFFFAOYSA-N 0.000 claims 1
- IWGYXSFAZPPOMV-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(B2OC(C)(C)C(C)(C)O2)=C1 IWGYXSFAZPPOMV-UHFFFAOYSA-N 0.000 claims 1
- YQMNZIMHJHNUIM-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-phthalazin-6-ylbenzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C=2C=C3C=NN=CC3=CC=2)=C1 YQMNZIMHJHNUIM-UHFFFAOYSA-N 0.000 claims 1
- NZOOIVRJLWIOIG-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-quinazolin-6-ylbenzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C=2C=C3C=NC=NC3=CC=2)=C1 NZOOIVRJLWIOIG-UHFFFAOYSA-N 0.000 claims 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 claims 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 claims 1
- 102000001332 SRC Human genes 0.000 claims 1
- 108060006706 SRC Proteins 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 150000001642 boronic acid derivatives Chemical class 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- WUCLNFFXNHSKFY-UHFFFAOYSA-N n-(3-isoquinolin-7-yl-4-methylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3C=NC=CC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 WUCLNFFXNHSKFY-UHFFFAOYSA-N 0.000 claims 1
- WEZAETNOOOWBEV-UHFFFAOYSA-N n-(3-isoquinolin-7-yl-4-methylphenyl)-4-(morpholin-4-ylmethyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3C=NC=CC3=CC=2)C(C)=CC=C1NC(=O)C(C=C1C(F)(F)F)=CC=C1CN1CCOCC1 WEZAETNOOOWBEV-UHFFFAOYSA-N 0.000 claims 1
- RDNJSLLWQJDVAN-UHFFFAOYSA-N n-(3-isoquinolin-7-yl-4-methylphenyl)-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(C(C)=CC=2)C=2C=C3C=NC=CC3=CC=2)C=C1C(F)(F)F RDNJSLLWQJDVAN-UHFFFAOYSA-N 0.000 claims 1
- HUEBBWXHQRJQBA-UHFFFAOYSA-N n-(4-methyl-3-phthalazin-6-ylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 HUEBBWXHQRJQBA-UHFFFAOYSA-N 0.000 claims 1
- PSRLFLMSZFBATQ-UHFFFAOYSA-N n-(4-methyl-3-phthalazin-6-ylphenyl)-4-(piperidin-1-ylmethyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1NC(=O)C(C=C1C(F)(F)F)=CC=C1CN1CCCCC1 PSRLFLMSZFBATQ-UHFFFAOYSA-N 0.000 claims 1
- ISHGNBGFTLNSCV-UHFFFAOYSA-N n-(4-methyl-3-phthalazin-6-ylphenyl)-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(C(C)=CC=2)C=2C=C3C=NN=CC3=CC=2)C=C1C(F)(F)F ISHGNBGFTLNSCV-UHFFFAOYSA-N 0.000 claims 1
- YBHJIMYXLDSGSR-UHFFFAOYSA-N n-(4-methyl-3-quinazolin-6-ylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3C=NC=NC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 YBHJIMYXLDSGSR-UHFFFAOYSA-N 0.000 claims 1
- GSDDFQPXMDVYOD-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-5-yl)-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3N=CSC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 GSDDFQPXMDVYOD-UHFFFAOYSA-N 0.000 claims 1
- BQNIEYQHHPDLJI-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-6-yl)-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3SC=NC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 BQNIEYQHHPDLJI-UHFFFAOYSA-N 0.000 claims 1
- JWCFBQGDEABLIJ-UHFFFAOYSA-N n-[3-(2-aminoquinazolin-6-yl)-4-methylphenyl]-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(C(C)=CC=2)C=2C=C3C=NC(N)=NC3=CC=2)C=C1C(F)(F)F JWCFBQGDEABLIJ-UHFFFAOYSA-N 0.000 claims 1
- DMXWAOUYXWLNOD-UHFFFAOYSA-N n-[4-[(dimethylamino)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-phthalazin-6-ylbenzamide Chemical compound C1=C(C(F)(F)F)C(CN(C)C)=CC=C1NC(=O)C1=CC=C(C)C(C=2C=C3C=NN=CC3=CC=2)=C1 DMXWAOUYXWLNOD-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 125000005717 substituted cycloalkylene group Chemical group 0.000 claims 1
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0417905.7 | 2004-08-11 | ||
| GBGB0417905.7A GB0417905D0 (en) | 2004-08-11 | 2004-08-11 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007108861A true RU2007108861A (ru) | 2008-09-20 |
Family
ID=33017336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007108861/04A RU2007108861A (ru) | 2004-08-11 | 2005-08-10 | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20060035897A1 (enExample) |
| EP (1) | EP1778640A1 (enExample) |
| JP (1) | JP2008509187A (enExample) |
| KR (1) | KR20070046851A (enExample) |
| CN (2) | CN101039914A (enExample) |
| AU (1) | AU2005270313A1 (enExample) |
| BR (1) | BRPI0514288A (enExample) |
| CA (1) | CA2575316A1 (enExample) |
| EC (1) | ECSP077235A (enExample) |
| GB (1) | GB0417905D0 (enExample) |
| IL (1) | IL181169A0 (enExample) |
| MA (1) | MA28822B1 (enExample) |
| MX (1) | MX2007001642A (enExample) |
| NO (1) | NO20071300L (enExample) |
| RU (1) | RU2007108861A (enExample) |
| TN (1) | TNSN07048A1 (enExample) |
| WO (1) | WO2006015859A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054916A1 (en) † | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| EP1878727A4 (en) * | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| CN102861338A (zh) * | 2006-04-05 | 2013-01-09 | 诺瓦提斯公司 | 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合 |
| KR20090029261A (ko) * | 2006-07-13 | 2009-03-20 | 노파르티스 아게 | 신경계 장애의 치료에서의 트리플루오로메틸-치환 벤즈아미드의 용도 |
| WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| US8673929B2 (en) | 2006-07-20 | 2014-03-18 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
| ATE501124T1 (de) * | 2006-09-05 | 2011-03-15 | Amgen Inc | Phthalazin-, aza- und diazaphthalazinverbindungen und anwendungsverfahren |
| EP2117544A4 (en) * | 2006-12-19 | 2010-03-03 | Univ Texas | BIOMARKER FOR IDENTIFYING REACTIVATION FROM STAT3 TO SRC INHIBITION |
| ES2415863T3 (es) * | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
| AU2008248073B2 (en) * | 2007-05-07 | 2011-03-24 | Amgen Inc. | Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use |
| US8022085B2 (en) * | 2007-05-07 | 2011-09-20 | Amgen Inc. | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof |
| US20100292292A1 (en) * | 2007-09-13 | 2010-11-18 | Link Medicine Corporation | Treatment of Neurodegenerative Diseases Using Indatraline Analogs |
| US8367671B2 (en) * | 2008-03-21 | 2013-02-05 | Amgen Inc. | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents |
| CN102015660A (zh) | 2008-04-23 | 2011-04-13 | 协和发酵麒麟株式会社 | 2-氨基喹唑啉衍生物 |
| US8455495B2 (en) | 2008-08-29 | 2013-06-04 | Amgen Inc. | Pyridazino-pyridinone compounds and methods of use |
| WO2010025202A1 (en) | 2008-08-29 | 2010-03-04 | Amgen Inc. | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF |
| US8772481B2 (en) | 2008-10-10 | 2014-07-08 | Amgen Inc. | Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof |
| WO2010042649A2 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF |
| WO2010096395A1 (en) * | 2009-02-18 | 2010-08-26 | Syntech Solution Llc | Amides as kinase inhibitors |
| CA2765030C (en) | 2009-06-09 | 2015-10-27 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| CN102573473B (zh) | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
| CN102573484B (zh) | 2009-06-09 | 2015-07-01 | 加利福尼亚资本权益有限责任公司 | 苄基取代的三嗪衍生物及其治疗应用 |
| CA2777128A1 (en) * | 2009-10-30 | 2011-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
| CN102675289B (zh) * | 2011-03-18 | 2014-11-05 | 浙江大德药业集团有限公司 | 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物 |
| EP2701507A1 (en) * | 2011-04-26 | 2014-03-05 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as b-raf inhibitors for treatment of cancer |
| DK3097102T3 (en) | 2015-03-04 | 2018-01-22 | Gilead Sciences Inc | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO [3,2-D] PYRIMIDINE COMPOUNDS |
| MA46093A (fr) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Composés modulateurs du recepteur de type toll |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| CN111904960A (zh) * | 2020-05-19 | 2020-11-10 | 合肥合源药业有限公司 | 一种固体分散体及药用组合物 |
| KR102463217B1 (ko) * | 2020-07-13 | 2022-11-07 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 4-아미노퀴나졸린-2-카복스아미드 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
| CN111925331A (zh) * | 2020-07-14 | 2020-11-13 | 上海毕得医药科技有限公司 | 一种6-溴酞嗪的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6587829B1 (en) * | 1997-07-31 | 2003-07-01 | Schering Corporation | Method and apparatus for improving patient compliance with prescriptions |
| US6523009B1 (en) * | 1999-11-06 | 2003-02-18 | Bobbi L. Wilkins | Individualized patient electronic medical records system |
| US20030236682A1 (en) * | 1999-11-08 | 2003-12-25 | Heyer Charlette L. | Method and system for managing a healthcare network |
| US6684276B2 (en) * | 2001-03-28 | 2004-01-27 | Thomas M. Walker | Patient encounter electronic medical record system, method, and computer product |
| GB0217757D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
-
2004
- 2004-08-11 GB GBGB0417905.7A patent/GB0417905D0/en not_active Ceased
-
2005
- 2005-08-10 US US11/201,348 patent/US20060035897A1/en not_active Abandoned
- 2005-08-10 JP JP2007525252A patent/JP2008509187A/ja active Pending
- 2005-08-10 CA CA002575316A patent/CA2575316A1/en not_active Abandoned
- 2005-08-10 CN CNA200580034662XA patent/CN101039914A/zh active Pending
- 2005-08-10 RU RU2007108861/04A patent/RU2007108861A/ru not_active Application Discontinuation
- 2005-08-10 MX MX2007001642A patent/MX2007001642A/es not_active Application Discontinuation
- 2005-08-10 KR KR1020077003238A patent/KR20070046851A/ko not_active Withdrawn
- 2005-08-10 US US11/573,235 patent/US20080096883A1/en not_active Abandoned
- 2005-08-10 CN CN200910175026A patent/CN101696188A/zh active Pending
- 2005-08-10 AU AU2005270313A patent/AU2005270313A1/en not_active Abandoned
- 2005-08-10 EP EP05777531A patent/EP1778640A1/en not_active Withdrawn
- 2005-08-10 BR BRPI0514288-1A patent/BRPI0514288A/pt not_active IP Right Cessation
- 2005-08-10 WO PCT/EP2005/008695 patent/WO2006015859A1/en not_active Ceased
-
2007
- 2007-02-05 IL IL181169A patent/IL181169A0/en unknown
- 2007-02-09 TN TNP2007000048A patent/TNSN07048A1/en unknown
- 2007-02-09 EC EC2007007235A patent/ECSP077235A/es unknown
- 2007-02-22 MA MA29711A patent/MA28822B1/fr unknown
- 2007-03-09 NO NO20071300A patent/NO20071300L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP077235A (es) | 2007-03-29 |
| WO2006015859A1 (en) | 2006-02-16 |
| CA2575316A1 (en) | 2006-02-16 |
| JP2008509187A (ja) | 2008-03-27 |
| US20080096883A1 (en) | 2008-04-24 |
| MX2007001642A (es) | 2007-04-10 |
| TNSN07048A1 (en) | 2008-06-02 |
| US20060035897A1 (en) | 2006-02-16 |
| KR20070046851A (ko) | 2007-05-03 |
| BRPI0514288A (pt) | 2008-06-10 |
| CN101696188A (zh) | 2010-04-21 |
| AU2005270313A1 (en) | 2006-02-16 |
| CN101039914A (zh) | 2007-09-19 |
| MA28822B1 (fr) | 2007-08-01 |
| GB0417905D0 (en) | 2004-09-15 |
| NO20071300L (no) | 2007-04-19 |
| IL181169A0 (en) | 2007-07-04 |
| EP1778640A1 (en) | 2007-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008509187A5 (enExample) | ||
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| RU2324684C2 (ru) | Пиримидиновые производные | |
| US9309224B2 (en) | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| US20160046619A1 (en) | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| RU2006105101A (ru) | Арилокси и арилалкиленокси замещенные имидазохинолины | |
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| RU2003116648A (ru) | Замещенные имидазопиридины | |
| MXPA04009784A (es) | Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas. | |
| RU2006110186A (ru) | Алкокси замещенные имидазохинолины | |
| RU2015106787A (ru) | Замещенные пирролы, активные в качестве ингибиторов киназ | |
| JP2005519908A5 (enExample) | ||
| EA200300424A1 (ru) | Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов | |
| RU2003121307A (ru) | (диазоло-пиридинил)-пиримидины для применения в лечении нарушений центральной нервной системы и диабета | |
| PT2420491E (pt) | Compostos de piperidina 3,5-substituída como inibidores de renina | |
| RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| PE20050420A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| MXPA05011270A (es) | Compuestos de imidazopiridina que tienen actividad agonista del receptor 5-ht4 y actividad antagonista del receptor 5-ht3. | |
| RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
| KR20240102970A (ko) | 인테그린 억제제 및 다른 작용제와 조합된 그의 용도 | |
| JP2005538111A5 (enExample) | ||
| RU2012109220A (ru) | Новые соединения и их терапевтическое использование для ингибирования протеинкиназы | |
| RU2006120486A (ru) | Гидроксиалкилзамещенные пиридо-7-пиримидин-7-оны |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100504 |